Does Lupus Lower AMH? Autoimmune Disease and Ovarian Reserve
Can autoimmune disease like lupus actually cause your AMH to drop?
Yes. There is a documented mechanism — autoimmune oophoritis — in which the same immune process driving lupus or another autoimmune condition targets ovarian tissue directly, independent of gonadotoxic drugs like cyclophosphamide. A separate point gets confused with it constantly: a medication's instruction to avoid pregnancy is usually about protecting a future pregnancy from drug exposure, not evidence that the drug is depleting your ovarian reserve. Those are two different concerns and they deserve different levels of worry.
What is autoimmune oophoritis, and why does it show up as falling AMH?
This is genuinely different from the cause most often discussed in autoimmune disease — gonadotoxic treatment such as cyclophosphamide. Autoimmune oophoritis describes the immune response reaching ovarian tissue itself: lymphocytes infiltrate the ovary, antibodies against ovarian targets (including granulosa cells, the zona pellucida and steroidogenic enzymes) can be detected, and the resulting chronic inflammation drives cell death in ovarian tissue.
The histology is what makes the AMH connection concrete. In autoimmune ovarian disease, the inflammatory infiltrate concentrates around the growing follicles — preantral and antral — while primordial follicles are typically spared. AMH is secreted specifically by those small growing follicles, so damage aimed at exactly that population shows up in bloodwork as a falling AMH before anything obvious happens to the menstrual cycle.
How strong is the evidence that the disease itself lowers ovarian reserve?
Stronger than most patients are told, and it does not depend on chemotherapy-type drugs. A 2024 systematic review and meta-analysis in Joint Bone Spine pooled thirteen studies (1,017 women) comparing lupus patients with healthy controls and found significantly lower AMH (weighted mean difference −1.07 ng/mL, 95% CI −1.37 to −0.76) and lower antral follicle counts (WMD −3.46, 95% CI −4.57 to −2.34), with no significant overall difference in FSH. The effect was clearest in adult-onset disease (AMH WMD −1.44, 95% CI −1.71 to −1.18); in juvenile-onset lupus the AMH difference was not statistically significant, though antral follicle counts still were.
Two details matter for anyone whose treatment has never included cyclophosphamide. First, a study in Lupus (2011) measured AMH in 33 premenopausal lupus patients who had never received cyclophosphamide and found significantly lower values than in age-matched healthy controls — and later work adding antral follicle counts reached the same conclusion. Second, that 2011 study found no correlation between AMH and either disease duration or SLEDAI disease-activity score, so a low reserve is not simply a marker of how severe or long-standing the disease has looked. There is also evidence that a high cumulative dose of methotrexate is associated with subclinical ovarian dysfunction in adults with childhood-onset lupus, which is a separate signal from cyclophosphamide.
What that adds up to in a consultation: if you are managing an autoimmune condition on medications not usually considered gonadotoxic and your AMH is still falling, the disease process itself is a legitimate, evidence-backed explanation — not a mystery your doctors have failed to solve.
Can steroid treatment for flares lower AMH as well?
Here the honest answer is narrower than it is often stated. High-dose glucocorticoids — used for flares — do suppress the hypothalamic-pituitary-ovarian axis; that has been shown in healthy women given exogenous steroid and in states of endogenous cortisol excess, with reduced gonadotropin and progesterone levels. What follows from that is disturbed cycles and altered ovarian hormone signaling, not proven follicle loss: AMH production by small follicles is largely independent of gonadotropins, and direct evidence that steroid bursts lower AMH in people is limited. So steroids belong on the list of things to separate out when you are trying to explain a specific AMH change — and they are a more plausible explanation for an irregular cycle than for a depleted reserve. Our piece on reading AMH and antral follicle count together covers why one marker in isolation rarely tells the whole story.
What about hydroxychloroquine — does it damage ovarian reserve?
Hydroxychloroquine is not an alkylating agent, and there is no human evidence that it depletes ovarian reserve; animal work actually points the other way, with protective effects on ovarian function in induced models of premature ovarian insufficiency. That is a useful thing to know, because women on hydroxychloroquine who watch their AMH fall often assume the drug is the culprit. The evidence above suggests the disease is the more likely driver. Any decision to start, stop or change an autoimmune medication belongs to your rheumatologist or prescribing physician — this is background for that conversation, not a substitute for it.
Does an "avoid pregnancy" warning mean a medication damages fertility?
Usually not, and this is one of the more consequential points of confusion in medication counseling. When a label says to avoid pregnancy during treatment, that instruction is generally about protecting a hypothetical fetus from drug exposure — based on animal reproduction studies, or simply on a lack of human safety data — not a statement that the drug harms egg supply or ovarian reserve. The two concerns get collapsed into one sentence constantly, and "you shouldn't get pregnant on this" is easily misread as "this is going to cost you your fertility."
A concrete, checkable example: rilonacept (ARCALYST), an interleukin-1 blocker used for recurrent pericarditis and certain rare inflammatory syndromes, carries a pregnancy warning based on animal data. Reading the actual label, the embryo-fetal study in monkeys found no treatment-related effects on fetal survival or malformations at exposures up to roughly eleven times the maximum recommended human dose; what it did find was an increased incidence of lumbar ribs — a skeletal variation — at about twice that dose and higher, plus rib and vertebral findings in a single fetus from the one animal exposed later in gestation, an association the label itself describes as unclear. Every one of those findings concerns a fetus that is already exposed in utero. In the separate fertility testing, a mouse analog of the drug had no effect on fertility or reproductive performance in male or female animals.
That is a meaningfully different situation from a genuinely gonadotoxic drug like cyclophosphamide, which damages ovarian follicles whether or not a pregnancy is attempted. Not every medication with a pregnancy warning has been through fertility-specific testing, which is exactly why this is worth asking your prescriber directly: is this restriction about protecting a fetus during pregnancy, or is there actual evidence of an effect on ovarian reserve itself?
What should you do if you are managing both an autoimmune condition and fertility goals?
If reduced ovarian reserve has already been documented and your treatment plan involves an extended period of required contraception, that combination is a reasonable basis for asking your rheumatologist for a direct referral to a reproductive endocrinologist to discuss fertility preservation — independent of how any single medication's mechanism gets clarified. Ovarian reserve testing repeated over time is more informative than one number, and an antibody result picked up along the way — for example a positive lupus anticoagulant while you wait on confirmatory testing — deserves its own interpretation rather than being folded into the reserve question. It is also worth having the immune and metabolic side of the picture evaluated alongside it, rather than in a separate conversation. At our Huntington clinic we see this multi-specialty pattern often across Long Island and New York City, where rheumatology and fertility planning are running in parallel and nobody is looking at both at once. Our Metabolic & Immune Fertility Evaluation is built for that, and our piece on how immune testing is used in a fertility workup explains which markers are actually informative.
What is the bottom line?
Autoimmune disease can lower AMH through a documented mechanism — immune-driven damage to the growing follicles in the ovary — independent of chemotherapy-type drugs, so a meaningful AMH decline alongside an autoimmune diagnosis deserves to be taken seriously as a real, connected finding rather than a coincidence. Separately, a medication's instruction to avoid pregnancy is usually about protecting a future pregnancy, not a sign the drug is depleting your eggs, and your prescriber can tell you which concern applies to your specific medication. Getting those two questions separated is what turns a frightening, vague picture into a set of decisions you can actually make.
This article is for general educational purposes and is not a substitute for individualized guidance from your rheumatologist, prescribing physician, or reproductive endocrinologist. Questions about specific medications and fertility should be directed to the physicians managing each part of your care.
East to West Fertility is a metabolic and immune-focused fertility clinic in Huntington, Long Island, serving patients across Long Island, NYC, and beyond. Learn more about our Metabolic & Immune Fertility Evaluation or call 631-416-4940.
References:
- Effect of systemic lupus erythematosus on the ovarian reserve: a systematic review and meta-analysis. Joint Bone Spine 2024;91(4):105728. doi:10.1016/j.jbspin.2024.105728.
- Impact of systemic lupus erythematosus on ovarian reserve in premenopausal women: evaluation by using anti-Muellerian hormone. Lupus 2011;20(11):1193-1197. PubMed 21768179.
- Evaluation of the ovarian reserve in women with systemic lupus erythematosus. J Family Reprod Health 2021;15(1). doi:10.18502/jfrh.v15i1.6076.
- Ovarian reserve in adult patients with childhood-onset lupus: a possible deleterious effect of methotrexate? Scand J Rheumatol 2014. PubMed 24881927.
- Ovarian function in patients with systemic lupus erythematosus: pathogenesis, drug application and prospective therapies. World J Exp Med 2024;14(2):88867. PMC11212741.
- Ovarian autoimmune disease: clinical concepts and animal models. PMC4220844.
- Suppression of the hypothalamic-pituitary-ovarian axis in normal women by glucocorticoids. Obstet Gynecol Surv 1994.
- Hydroxychloroquine protects against autoimmune premature ovarian insufficiency by modulating the Treg/Th17 cell ratio in BALB/c mice. Am J Reprod Immunol 2023;89(4):e13686.
- ARCALYST (rilonacept) Prescribing Information, sections 8.1 and 13.1. FDA label via DailyMed.
